NCT02040298View on ClinicalTrials.gov

Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

April 30, 2016

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Clemastine

4mg tablet twice daily

DRUG

Placebo

Placebo tablet twice daily

Trial Locations (1)

94518

UCSF Multiple Sclerosis Center, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT02040298 - Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis | Biotech Hunter | Biotech Hunter